Mercks diabetes eye drug meets trial goal
Merck reported that its injectable drug remigromig was as effective as standard treatment in a late-stage trial for diabetic macular edema. The experimental therapy aims to repair retinal blood vessels. Shares climbed following the announcement.
Xurve View
Insights:
Xurve View
Merck & Co. Inc. reported that its experimental injectable drug remigromig met primary goals in a 52-week clinical study of 984 diabetic macular edema patients on Thursday afternoon. The treatment matched the efficacy of standard care in improving visual sharpness. Regulatory approval would introduce the first novel mechanism of action for retinal vascular diseases in more than two decades, according to Scotiabank analyst Louise Chen.
